drugset / Trial / NCT00207142

Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)

NCT00207142

Phase 4 Completed 252 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the proportion of subjects with HIV-1 RNA viral load \< 50 c/mL through Week 48 of the Maintenance Phase among HIV-infected subjects with an initial undetectable viral load following an Induction Phase with an ATV/RTV containing HAART regimen, when switched to ATV versus remaining on ATV/RTV, whilst continuing their previous NRTI backbone.

Timeline

Start
2005-11
Primary completion
2007-08
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified 300 mg Oral
Subject Atazanavir Other / unclassified 400 mg Oral
Subject Ritonavir Other / unclassified 100 mg Oral